Every material Form 8-K Boston Scientific filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Boston Scientific's Board approved its 2026 Annual Bonus Plan and two 2026 performance share programs on November 18, 2025, covering the performance period from January 1, 2026 through December 31, 2028. The filing describes compensation terms for employees and executives, including payout ranges tied to sales, earnings and total shareholder return, but it does not report any financial results or new financial figures.
Board approved the 2026 Annual Bonus Plan on November 18, 2025, for the performance year January 1 to December 31, 2026.
Bonus pool payouts are set by the Compensation Committee at 0% to 150% of target, based on global sales, adjusted EPS, operating income and sustainability goals.
Two performance share programs cover January 1, 2026 to December 31, 2028, with awards of 0% to 200% of target based on relative total shareholder return and organic net sales growth.
Boston Scientific director John E. Sununu told the company on October 22, 2025, that he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He will remain a director and keep his committee roles until that meeting, and the company says the decision is not the result of any disagreement.
Sununu has served on the Board since April 2009.
He currently sits on the Audit Committee and chairs the Nominating and Governance Committee.
He will continue as a director until the 2026 Annual Meeting.
The Board will evaluate whether to add directors after his departure.
Boston Scientific reported third-quarter 2025 net sales of $5.065 billion, up 20.3% on a reported basis and 15.3% on an organic basis from a year earlier. GAAP EPS was $0.51 and adjusted EPS was $0.75, both above the company's prior guidance ranges. The company also gave fourth-quarter and full-year 2025 guidance, estimating full-year reported net sales growth of about 20%.
Q3 reported net sales of $5.065 billion, up 20.3%, versus guidance of 17% to 19%
GAAP EPS of $0.51 versus guidance of $0.44 to $0.46; adjusted EPS of $0.75 versus guidance of $0.70 to $0.72
Q4 2025 guidance: reported net sales growth of 14.5% to 16.5%; GAAP EPS of $0.48 to $0.52; adjusted EPS of $0.77 to $0.79
Company discontinued worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems in Q2 2025, which had prior year global sales of about $50 million per quarter
Boston Scientific said Executive Vice President and President of Peripheral Interventions Jeffrey B. Mirviss will retire from that role effective December 1, 2025, and will then serve as a senior advisor through February 27, 2026. The company expects to sign a retirement agreement with him with payments and benefits materially consistent with existing plans, which matters to shareholders mainly as a routine leadership transition in one business unit.
Mirviss informed the company of his retirement decision on August 29, 2025.
Retirement from his executive role takes effect December 1, 2025.
He will stay on as a senior advisor until the Retirement Date, no later than February 27, 2026, at his current $705,000 annual base salary, prorated.
A Retirement Agreement is expected, with terms materially consistent with existing executive retirement, bonus and long-term incentive plans.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Boston Scientific filing is on SEC EDGAR ↗. 8-K briefs of other companies →